{"title":"不再落后PD-1 有了新的免疫疗法伙伴","authors":"Andrew J. Gunderson","doi":"10.1016/j.immuni.2024.09.010","DOIUrl":null,"url":null,"abstract":"PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in <em>Cell</em> illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms.","PeriodicalId":13269,"journal":{"name":"Immunity","volume":"5 1","pages":""},"PeriodicalIF":25.5000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LAGging behind no more: PD-1 has a new immunotherapy partner\",\"authors\":\"Andrew J. Gunderson\",\"doi\":\"10.1016/j.immuni.2024.09.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in <em>Cell</em> illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms.\",\"PeriodicalId\":13269,\"journal\":{\"name\":\"Immunity\",\"volume\":\"5 1\",\"pages\":\"\"},\"PeriodicalIF\":25.5000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.immuni.2024.09.010\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.immuni.2024.09.010","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
LAGging behind no more: PD-1 has a new immunotherapy partner
PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in Cell illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms.
期刊介绍：
Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
